New drug trial aims to restore skin color in vitiligo patients
NCT ID NCT07223229
Summary
This study is testing whether a new immune-targeting drug called EI-001 can help improve skin repigmentation in adults with non-segmental vitiligo. About 45 participants will be randomly assigned to receive either the drug or a placebo to compare results. The main goal is to see if EI-001 is safe and can reduce the area of skin affected by vitiligo, particularly on the face.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SEGMENTAL VITILIGO are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Linkou Chang Gung Memorial Hospital
RECRUITINGTaoyuan District, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Skin Care Research, LLC
NOT_YET_RECRUITINGHollywood, Florida, 33021, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
U Mass Chan Medical School Department of Dermatology
NOT_YET_RECRUITINGWorcester, Massachusetts, 01605, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.